NexPlasmaGen wins a Corporate Livewire Innovation & Excellence Award
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The...
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The...
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David...
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was...
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie...
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that...
Montreal / July 4, 2022 NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation...
Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference. The MedInvest Oncology Investor Conference will be hosted in...